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Abstract
Prostate cancer is a heterogeneous group of diseases and there is a need for more efficient and targeted methods of
treatment. In this study, the potential of gene expression data and RNA interference technique were combined to advance
future personalized prostate cancer therapeutics. To distinguish the most promising in vivo prevalidated prostate cancer
drug targets, a bioinformatic analysis was carried out using genome-wide gene expression data from 9873 human tissue
samples. In total, 295 genes were selected for further functional studies in cultured prostate cancer cells due to their high
mRNA expression in prostate, prostate cancer or in metastatic prostate cancer samples. Second, RNAi based cell viability
assay was performed in VCaP and LNCaP prostate cancer cells. Based on the siRNA results, gene expression patterns in
human tissues and novelty, endoplasmic reticulum function associated targets AIM1, ERGIC1 and TMED3, as well as mitosis
regulating TPX2 were selected for further validation. AIM1, ERGIC1, and TPX2 were shown to be highly expressed especially
in prostate cancer tissues, and high mRNA expression of ERGIC1 and TMED3 associated with AR and ERG oncogene
expression. ERGIC1 silencing specifically regulated the proliferation of ERG oncogene positive prostate cancer cells and
inhibited ERG mRNA expression in these cells, indicating that it is a potent drug target in ERG positive subgroup of prostate
cancers. TPX2 expression associated with PSA failure and TPX2 silencing reduced PSA expression, indicating that TPX2
regulates androgen receptor mediated signaling. In conclusion, the combinatorial usage of microarray and RNAi techniques
yielded in a large number of potential novel biomarkers and therapeutic targets, for future development of targeted and
personalized approaches for prostate cancer management.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy
and the second most common cause of cancer mortality in the
Western male population [1]. However, prostate cancers form a
heterogeneous group of diseases and some men are still diagnosed
with high-grade disease and ultimately fail treatment [1,2]. Despite
the phenotypic and molecular heterogeneity of the disease there is
a lack of robust and specific prognostic biomarkers to distinguish
between indolent and aggressive cancers at early phases of the
disease. Furthermore, due to the lack of efficient prognostic and
therapeutic biomarkers, as well as targeted therapeutics, the
clinical management is still far from personalized.
Besides regulating the development and maintenance of the
prostate, androgens support the development and growth of most
primary prostate cancers, and androgen receptor (AR) plays the
role of an oncogene in prostate cancer [3–7]. Accordingly,
androgen ablation is currently the treatment of choice for
advanced prostate cancer. However, although androgen blockage
initially results in a good treatment response, it is almost never
curative [2]. Androgen-independent cancer cells typically start to
appear during therapy, eventually leading to recurrent, hormone-
refractory disease [8,9]. In addition to prevailing alterations in AR
expression and function, approximately half of prostate cancer
samples harbor an oncogenic gene fusion combining androgen-
regulated transmembrane protease serine 2 (TMPRSS2) with
oncogenic ETS transcription factors [10]. Most frequently, the
fusion partner is ERG (v-ets erythroblastosis virus E26 oncogene
homolog, avian), followed by ETV1 (ets variant 1), ETV4, and
ETV5 [11–13]. ERG mRNA is not expressed in healthy prostate
tissues, but as a result of the TMPRSS2-ERG gene fusion early in
carcinogenesis, a significant increase in ERG transcript levels can
be detected in prostate cancers. ETS gene fusions promote
multiple signaling pathways associated with cancer formation and
progression, and ectopic ERG oncogene expression has been
associated with a specific molecular signature in prostate cancer
[14–19]. Although ERG activation mediated oncogenic processes
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expression of ERG has been described to persist also in castration
resistant prostate cancer, supporting the importance of this
rearrangement also in advanced disease [15,20,21]. Taken
together, ETS fusions are key molecular alterations driving the
development and progression of a distinct class of prostate cancers,
and could therefore benefit from targeted therapy.
In recent years advanced molecular genetic techniques
combined with development of novel bioinformatic analysis tools
have offered efficient ways to examine tumor gene expression
profiles, which facilitates biomarker discovery, as well as
identification of potential novel drug targets. Gene expression
profiling enables improved diagnosis and staging of the disease,
provides information on treatment responses and leads to reduced
side effects [22,23]. RNA interference (RNAi) technique enables
the exploration of the functional effect of individual genes on
cancer cell characteristics, such as growth and survival, further
advancing the development of targeted and personalized ther-
apeutics [24–26]. In this study, the potential of these techniques
was combined by pre-selecting the genes for RNAi functional
assays using gene expression data. To identify potential vulner-
abilities present in prostate cancers, a bioinformatic mRNA
expression analysis was first carried out based on 9873 human
tissue samples, including 349 prostate cancer and 147 non-
malignant prostate samples, to distinguish prostate and prostate
cancer tissue specific genes. Second, a RNAi high-throughput
(HT) functional profiling of the selected in vivo prevalidated
possible drug targets was performed in VCaP and LNCaP prostate
cancer cell lines in order to identify genes and pathways essential
for prostate cancer cell proliferation and survival. The results
highlighted the potential of targeting endoplasmic reticulum (ER),
oxidation, actin cytoskeleton and mitosis in prostate cancer
management, and further validation identified AIM1 (absent in
melanoma 1), ERGIC1 (endoplasmic reticulum-Golgi intermediate
compartment protein 1), TMED3 (transmembrane emp24 protein
transport domain containing 3) and TPX2 (targeting protein for
Xklp2) as potential novel drug targets in prostate cancer.
Methods
In Silico Data Mining
The GeneSapiens database [27] was applied to bioinformati-
cally explore the gene expression levels across 9783 human tissue
samples. Briefly, GeneSapiens (http://www.genesapiens.org/) is a
collection of 9873 Affymetrix microarray experiments. All samples
are reannotated and normalized with a custom algorithm. The
data are collected from various publicly available sources,
including Gene Expression Omnibus and Array-Express and
covers 175 different tissue types. Mean expression of each gene
was determined in prostate cancer (n=349), healthy prostate
(n=147), and all normal tissue samples (n=1476). The data from
prostate cancer samples available in the GeneSapiens database
were utilized also in the in silico coexpression analyses. The
functional gene ontology annotations were analyzed for the co-
expressed genes (R .0.5 and P,0.001) using DAVID functional
annotation tool [28] and Ingenuity Pathway Analysis (IPA)
Software (Ingenuity Systems Inc., Redwood City, CA, USA).
Cell Culture
VCaP prostate cancer cells were received from Kenneth Pienta
(University of Michigan, MI) or purchased from American Type
Culture Collection (LGC Promochem AB, Bora ˚s, Sweden) and
grown in RPMI-1640 medium (Invitrogen, Carlsbad, CA).
LNCaP cells were received from Dr. Marco Cecchini (University
of Bern, Switzerland) and maintained in T-Medium (Invitrogen,
Carlsbad, CA). PC-3, DU145 and MDA-PCa-2b cells were
purchased from American Type Culture Collection (LGC
Promochem AB), and 22Rv1 cells from Deutsche Sammlung
von Microorganismen und Zellkulturen GmbH (DSMZ,
Braunschweig, Germany). The non-malignant EP156T prostate
epithelial cells were received from Dr. Varda Rotter (Weizmann
Institute of Science, Rehovot, Israel) and RWPE-1 cells purchased
from American Type Culture Collection (LGC Promochem AB).
Primary prostate epithelial cells (PrEc) were purchased from Lonza
(Lonza Group Ltd, Basel, Switzerland). Androgen-independent
LNCaPs and their parental counterparts were received from Dr.
Zoran Culig (Innsbruck Medical University, Austria) and were
grown in RPMI-1640 (Invitrogen) containing charcoal stripped or
normal fetal bovine serum, respectively. Synthetic androgen
R1881 was purchased from PerkinElmer.
Gene Knock-down Using RNA Interference
Before screening, cell number was titrated for both VCaP and
LNCaP cells separately to ensure that cell proliferation remained
in a linear-exponential phase throughout the experiment. For the
RNAi studies, four siRNAs per gene (HP GenomeWide, Qiagen)
were plated onto 384-well plates (Greiner Bio-One, Frickenhau-
sen, Germany), followed by addition of the transfection agent
(siLentFect lipid reagent; Bio-Rad Laboratories, Hercules, CA) in
Opti-MEM medium (Invitrogen) and an appropriate quantity of
cells (1500–2000 per well), using automated liquid handling robot
(Hamilton) and liquid dispenser (ThermoFisher). The final siRNA
concentration was 13 nM. AllStars negative control (scrambled
siRNA, Qiagen) and lipid only were used as negative controls,
siRNAs against KIF11 (kinesin family member 11; SI02653770)
and PLK1 (polo-like kinase 1; SI02223844) were used as positive
controls. For the validation experiments cells were transfected with
two siRNAs per gene (AIM1: SI03126704, SI03212846; ERGIC1:
SI03164763, SI04302872; TMED3: SI00746711, SI00746718;
TPX2: SI00097188, SI00097195) as described above in the
appropriate plates.
Cell Viability and Apoptosis Assay
CellTitre-Blue (CTB) and CellTiter-Glo (CTG) cell viability
assays (Promega), and ApoONE apoptosis (induction of caspase -3
and 7 activities) assay (Promega) were performed according to the
manufacturer’s instructions in response to 48 h or 72 h siRNA
treatment. The results were scanned with EnVision Multilabel
platereader (PerkinElmer/Wallac).
Normalization and Statistical Analysis of siRNA Screen
Results
The raw results obtained from cell viability and apoptosis assays
were normalized using B-score [29], and siRNAs reducing cell
viability by -2 SD from the median of the controls (corresponding
to P,0.05) in at least two of the screens or inducing apoptosis by 3
SD (corresponding to P,0.01) were considered antiproliferative or
pro-apoptotic hit siRNAs.
Clinical Prostate Tissue Samples
The 33 primary prostate tumor samples (19 ERG oncogene
positive and 14 ERG negative) and 3 non-malignant prostate
samples utilized in this study have been described previously [30].
Quantitative Reverse Transcriptase PCR
The validation of mRNA expression levels was performed using
TaqMan quantitative reverse transcriptase PCR (qRT-PCR)
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ogy, University of Turku). RNA samples extracted with RNeasy
Mini Kit (Qiagen) were reversely transcribed to cDNA (High
Capacity cDNA Reverse Transcription Kit, Applied Biosystems)
and PCR reaction samples were analyzed in 96-well or 384-well
format. Quantitative RT-PCR was performed using ABI Prism
7900 (Applied Biosystems) and quantitation was carried out using
the DDCT method with RQ manager 1.2 software (Applied
Biosystems). Three replicate samples were studied for detection of
target mRNA expression and b-actin was used as an endogenous
control. The primers and probes were designed and selected with
the help of Universal ProbeLibrary Assay Design Center (Roche
Diagnostics) (Supporting Table S1).
Western Blot Analysis
Whole-cell lysates were prepared using lysis buffer (62.5 mM
Tris, 1% SDS, 5%, b-mercaptoethanol 10% glycerol, bromophe-
nol blue). Antibodies used included anti-AR (1:1,000, NeoMar-
kers, Thermo Fisher Scientific Inc., Fremont, CA), anti-PSA
(1:1,000, A0562, DakoCytomation, Glostrup, Denmark), as well as
secondary Alexa Fluor (1:4,000, Molecular Probes, Invitrogen)
antibodies. b-actin (1:5,000, antibody from Sigma) was used as a
loading control. The signal was detected using Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE) according to
the manufacturer’s instructions.
Statistical Analysis
The results are presented as the mean 6 SD. Statistical analyses
were performed using Student’s t-test (*, P,0.05; **, P,0.01; ***,
P,0.001) and Pearson correlation coefficient.
Results
High-throughput Screening Results Highlight the Role of
Endoplasmic Reticulum and Mitosis Related Genes in
Regulating Prostate Cancer Cell Growth and Survival
To select in vivo prevalidated potential drug targets and
biomarkers for further studies in cultured prostate cancer cells
the gene expression data available in GeneSapiens database was
utilized. In total, 295 prostate and/or prostate cancer specific
genes were selected based on high mRNA expression in prostate,
prostate cancer or in metastatic prostate cancer tissue samples, and
an siRNA library was constructed for functional studies (Figure 1).
For the RNAi studies 4 siRNAs per gene were purchased and plate
based HT siRNA screens were performed with VCaP and LNCaP
prostate cancer cell lines. VCaP is a model for TMPRSS2-ERG
positive prostate cancer, expressing wild type AR, whereas
LNCaPs harbour a mutant AR (T877A) with extended ligand
specificity. To identify therapeutically relevant genes and pathways
in prostate carcinogenesis, changes in cell viability and induction
of apoptosis (caspase -3 and 7 activation) were studied as the end-
points (Supporting Table S2).
The cell viability siRNA screen was performed in three
replicates and the apoptosis assay once in both cell lines. The
positive control siRNAs targeting known key regulators of the
mitotic progression as well as prostate cancer cell proliferation,
KIF11 and PLK1 [31,32], were able to significantly decrease cell
viability (Figure 2A) confirming thus transfection efficiency. The
replicate cell viability screens positively correlated (0,67, R ,0,78
in LNCaP and 0,36, R ,0,66 in VCaP) in both cell lines
supporting the functionality of the primary screens (Figure 2B and
Supporting Table S2).
The siRNA screens resulted in 94 potential proliferation
promoting (hits in at least two of the cell viability screens) and
97 anti-apoptotic genes in LNCaP cells. Out of the 94 reproduced
cell viability hit genes 45 (47.9%) were also anti-apoptotic. In
VCaP cells the final hit rate was 35 reproduced proliferation
promoting and 34 anti-apoptotic hit genes, 9 (25.7%) of which
promoted cell viability and protected from apoptosis. Silencing of
17 genes resulted in an anti-proliferative response in both LNCaP
and VCaP cells. (Figure 2B-C and Supporting Table S2).
The in silico co-expression analysis of proliferation hit genes
(n=112) suggested three major prostate cancer sub groups with
different mechanisms for cell growth regulation. The largest set of
genes had a role in ER and Golgi apparatus, prostate gland
development, as well as in oxidation reduction. The other
subgroups of prostate cancer viability regulating genes were
involved in actin cytoskeleton and mitosis (Figure 2D).
Novel Putative Prostate Cancer Drug Targets AIM1,
ERGIC1, TMED3, and TPX2 were Selected for Further
Validation
The RNAi screens confirmed the role of multiple previously
published prostate cancer drug targets as growth and apoptosis
regulating genes in cultured prostate cancer cells. Among others,
these genes included CLDN3, CYP4F8, EPHX2, FAAH, FOXA1,
MTDH, ODC1, PLA2G2A, PLA2G7, SIM2 and UBE2C [30,33–41]
(Supporting Table S2).
Four novel candidate drug targets, AIM1, ERGIC1, TMED3,
and TPX2, were selected for further studies based on the high
expression in prostate cancer compared to normal prostate and all
other normal tissues included in GeneSapiens database (Support-
ing Figure S1), as well as their novelty as regulators of prostate
cancer cell proliferation and apoptosis. AIM1, TMED3 and TPX2
were among the 17 genes, the silencing of which induced
antiproliferative effects in both VCaP and LNCaP cells as well
as apoptosis in at least one of the cell lines. Silencing of ERGIC1
induced antiproliferative effect specifically in the ERG oncogene
positive VCaP cells (Supporting Table S2). AIM1, ERGIC1 and
TMED3 were co-expressed in the set of genes functionally
annotated to ER and Golgi apparatus and redox reactions,
whereas TPX2 was expressed among the genes involved in mitosis
(Figure 2D).
AIM1 protein is a member of the bc-crystalline superfamily.
Unlike other b- and c-crystallines, known to be specifically
expressed in elongating lens fiber cells that are undergoing large
changes in cytoskeletal architecture and composition, AIM1 has a
non-lens role. However, AIM1 protein sequence has a weak
similarity with filament or actin-binding proteins, indicating a
possible role in the management of cell morphology and shape
[42]. AIM1 gene localizes in 6 q21, within the putative tumor
suppressor region for human melanoma, and AIM1 expression has
been shown to be altered in association with tumor suppression in
a human melanoma model [43]. However, recent studies
indicated that AIM1 is not the main tumor suppressor gene in
del6q21 in natural killer cell malignancies [44,45]. Supporting the
possible role of AIM1 as a tumor suppressor, AIM1 methylation
has been associated with nasopharyngeal carcinoma and primary
tumor invasion of bladder cancer [46,47]. On the other hand,
AIM1 expression has been shown to be high in TRAIL resistant
cancer cell lines [48].
ERGIC1 is a cycling membrane protein contributing to the
membrane traffic and selective transport of cargo between the ER,
the intermediate compartment, and the Golgi apparatus [49],
whereas TMED3 is a constituent of the coated vesicles that are
involved in the transportation of cargo molecules from the ER to
the Golgi complex and function as receptors for specific secretory
cargo [50]. Although the exact role of ERGIC1 and TMED3 in
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and ER is known to induce a stress response (unfolded protein
response) leading to apoptosis in cancer cells [51,52].
TPX2 is exclusively expressed in proliferating cells from the
transition G1/S until the end of cytokinesis. Mitosis is a major
biological process deregulated in cancer and the main biological
process targeted by cytotoxic drugs. Interestingly, TPX2 is known
to be highly expressed in various cancer tissues, and it has been
suggested as a biomarker for poor prognosis [53–55]. As an
important regulator of cell cycle and a binding partner for Aurora
A kinase, TPX2 has been suggested also as a potential drug target
in multiple malignancies [56–58]. However, TPX2 has not been
studied in prostate cancer previously. It has been suggested that
TPX2 targeted therapeutics could be more efficient than the use of
Aurora A kinase inhibitors due to the unspecific nature of
conventional kinase inhibitors [58]. Furthermore, combining
TPX2 and Aurora A kinase targeted therapeutics could inhibit
the development drug resistance [59,60].
Validation of AIM1, ERGIC1, TMED3, and TPX2 Expression
and siRNA Induced Target Gene Silencing in Cultured
Prostate Cells
The mRNA expression of AIM1, ERGIC1, TMED3, and TPX2
was studied in six prostate cancer (VCaP, PC-3, MDA-PCa-2b,
LNCaP, DU145 and 22Rv1) and three non-malignant prostate
epithelial cell lines (RWPE-1, PrEc, EP156T) (Figure 3A).
Especially ERGIC1 and TMED3 were found to be highly expressed
in the cancer but not in the non-malignant cell lines. Among the
malignant cell lines AIM1, ERGIC1, and TMED3 were most highly
expressed in VCaP, and TPX2 in LNCaP cells. Two siRNAs per
gene, chosen based on the target silencing efficacy, were selected
for validation studies (Figure 3B and Supporting Figure S2). The
results from 72 h cell viability and apoptosis assay confirmed the
antiproliferative effect of TMED3 and TPX2 silencing in both of
the cell lines. As expected based on the screening results, ERGIC1
had a role specifically in the ERG oncogene expressing VCaP cell
viability. However, although AIM1 siRNAs were able to decrease
VCaP cell viability, no consistent effects were observed in LNCaP
cells (Figure 3C). The caspase 3/7 activity was enhanced mainly in
response to TPX2 and TMED3 silencing in LNCaP cells, whereas
TPX2 and ERGIC1 silencing induced apoptosis in VCaP cells
with both siRNAs (Figure 3D).
AIM1, ERGIC1, and TPX2 are Highly Expressed in Clinical
Prostate Cancer Samples
Validation of target gene expression patterns in clinical prostate
samples confirmed that AIM1, ERGIC1, and TPX2 mRNA levels
were significantly elevated in prostate cancer tissues (n=33),
compared to non-malignant control tissue samples (n=3). All
cancer samples expressed AIM1 mRNA at higher levels than any
of the non-malignant samples; while ERGIC1 was over-expressed
in 94% (n=31), and TPX2 in 64% (n=23) of the cancer samples.
However, despite the promising results of TMED3 expression
patterns in cultured prostate cells, TMED3 mRNA was expressed
at equal levels in the non-malignant and cancer tissues (Figure 4A).
For comparison, mRNA levels for the key prostate cancer
oncogenes AR and ERG were also determined in the same
clinical samples, and the results are presented as a heatmap in
Figure 4B. Out of the four potential novel target genes, ERGIC1
(R=0.51) and TMED3 (R=0.69) expression patterns correlated
most significantly with AR expression (Figure 4C). In addition,
although ERGIC1 and TMED3 were highly expressed in both
ERG negative and positive prostate cancers, their mRNA
expression levels positively correlated with ERG expression levels
in ERG positive samples (P=0.002 and P=0.007 respectively)
(Figure 4D). Comparison of target gene expression with clinical
parameters revealed that AIM1 correlated significantly (P=0.03)
with young age (,60 years) (Figure 4E). In addition, high TPX2
expression correlated with prostate-specific antigen (PSA) failure
(P=0.02), and associated with high WHO grade and young age
(Figure 4F). No such associations were found with ERG1C1 or
TMED3 mRNA expression.
AIM1, ERGIC1, TMED3, and TPX2 are all Regulated by ERG
Oncogene and androgens in Cultured Prostate Cancer
Cells
To evaluate the potential role of ERG and AR in the regulation
of these prostate cancer cell growth promoting genes, the effect of
ERG and AR silencing, as well as androgen deprivation and
stimulation on target gene expression was analyzed. Surprisingly,
ERG silencing significantly decreased the mRNA expression of all
four target genes in VCaP cells (Figure 5A). Furthermore, AR
silencing decreased the mRNA expression of AIM1 in LNCaP cells
and TPX2 in both VCaP and LNCaP cells, whereas the expression
of TMED3 mRNA was increased (Figure 5B). Surprisingly,
although ERG1C1 expression was associated with AR and AR
driven ERG expression in clinical prostate cancers, no major
changes were observed in the expression of ERGIC1 mRNA
expression in response to AR silencing. Despite the diverse effects
of AR silencing on target gene expression, androgen deprivation
decreased and the synthetic androgen R1881 induced the
expression of all of the target genes in LNCaP cells in comparison
to the expression levels detected in androgen deprived conditions
(Figure 5C). The expression of the target genes was studied also in
LNCaP derivatives cultured in stable androgen ablated conditions
mimicking castration-resistant tumors. The results show a
significant increase in AIM1 expression in the ablated cells in
comparison to the parental cells cultured in normal media
(Figure 5D).
Taken together, these results suggest that the expression of the
potential novel drug targets AIM1, ERGIC1, TMED3, and TPX2 is
promoted by ERG oncogene and androgens in cultured prostate
cancer cells. Furthermore, AR silencing decreases the expression of
AIM1 and TPX2 in normal cell culture conditions, whereas AIM1
expression is stimulated in cells cultured in androgen deprived
conditions.
TPX2 Inhibition Suppresses AR Signaling in Cultured
Prostate Cancer Cells
Due to the function of AR as an important oncogene in prostate
cancer, the effect of AIM1, ERGIC1, TMED3, and TPX2
expression on AR signaling was analyzed. The results showed,
that although no consistant changes were observed in the protein
expression of AR and PSA in response to AIM1, ERGIC1 and
Figure 1. RNAi library target gene expression in silico. A heatmap presentation of the mean gene expression levels of the 295 genes (x-axis)
selected for further RNAi exploration in all of the tissues (healthy and malignant) present in GeneSapiens database (y-axis). The position of prostate
cancer (upper asterisk) and healthy prostate (lower asterisk) have been indicated. The colour illustrates the level of expression in different tissues, and
grey missing values. The heatmap is drawn based on unsupervised hierarchical clustering.
doi:10.1371/journal.pone.0039801.g001
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PSA expression in both VCaP and LNCaP cell lines, as well as to
decrease AR expression in LNCaP cells (Figure 5E and
Supporting Figure S3A). Furthermore, qRT-PCR results con-
firmed that TPX2 regulates the expression of AR and PSA already
at mRNA level (Supporting Figure S3B).
In order to illustrate the potential of the selected putative targets
in the treatment of hormone-refractory disease, the efficacy of
AIM1, ERGIC1, TMED3, and TPX2 silencing in the inhibition of
Figure 2. HT RNAi screening results. A. Overview of the normalized LNCaP and VCaP cell viability screen results (B-score). The results from the
positive control siRNAs (KIF11 and PLK1) are indicated in blue, negative control wells (AllStars negative scrambled siRNA and buffer only) in green,
and target gene siRNAs in gray. B. A heatmap presentation of the cell viability screen results (B-score). The assay was repeated three times in both
LNCaP and VCaP prostate cancer cell lines. Blue colour indicated decreased cell viability, red increased cell viability. The heatmap is drawn based on
unsupervised hierarchical clustering. C. The overlap between the RNAi screen hit genes (decreased cell viability in response to silencing) in LNCaP
and VCaP cell lines. D. In silico co-expression analysis of cell viability hit genes in prostate cancer samples. The genes are organized in the same order
in both y- and x-axis, and the correlations (R) between the genes are indicated with colours. Red indicates positive correlation, blue negative
correlation.
doi:10.1371/journal.pone.0039801.g002
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studied. The results support the potential of TPX2 in the
treatment of castration-resistant tumors and highlight the induc-
tion of apoptosis due to AIM1 and TMED3 inhibition especially in
the androgen independent cancer cells (Supporting Figure S4).
ERGIC1 Silencing Reduces the mRNA Expression of ERG
in vitro
Since ERGIC1 and TMED3 expression correlated with ERG
expression levels in ERG positive primary prostate tumors, the
potential effect of their expression on ERG mRNA expression was
studied in VCaP cell line. The results indicated that ERGIC1
silencing was able to systematically downregulate ERG mRNA
expression, although the results did not reach statistical signifi-
cance with both siRNAs studied (Supporting Figure S5).
In Silico Co-expression Analysis Connects AIM1, ERGIC1,
TMED3 and TPX2 to Carcinogenesis
To investigate the potential role of the four putative target genes
in prostate cancer, in silico co-expression signatures in clinical
prostate cancer samples were analysed (Table 1 and Supporting
Table S3). The results showed that ERGIC1 and TMED3 are
expressed in the same samples as genes involved in protein
transport at ER and Golgi apparatus, whereas TPX2 is expressed
together with genes involved in mitosis. Furthermore, cancer was
among the top disease processes associated with the co-expressed
genes for both ERGIC1 and TPX2. Genes co-expressed with AIM1
locate in ribosomes and mitochondrion, and have a role in the
regulation of cell morphology. In addition, high AIM1 and TMED3
expression associates with genes involved in lipid metabolism, and
high ERGIC1 and TMED3 expression with genes involved in redox
homeostasis.
Discussion
Accumulating gene expression data from human tissues provide
important information for identification of novel biomarkers and
drug targets for personalized medicine. In addition, high-
throughput cell-based RNAi screening enables functional valida-
tion of the candidate drug targets in an efficient manner [24–26].
In this study, the potential of these techniques was combined in
order to identify genes that play critical roles in regulating prostate
cancer cell proliferation and viability. Moreover, the expression of
the novel candidate drug targets was validated in a set of clinical
prostate cancer samples to evaluate further their potential as
targets for future personalized prostate cancer therapeutics.
A bioinformatic gene expression analysis was carried out using
GeneSapiens database [27] to distinguish the most promising in
vivo prevalidated prostate cancer drug targets for further studies in
cultured prostate cancer cells. In total, 295 genes were selected
based on their high mRNA expression levels in prostate, prostate
cancer or in metastatic prostate cancer samples. By utilizing this
gene expression based pre-selection approach instead of a
commercial ready made siRNA libraries, we aimed at maximizing
the focus on prostate and prostate cancer relevant genes. In
addition, other possible benefits accomplished by pre-selecting the
genes for RNAi functional assays include development of targeted,
personalized and efficient therapies with less unwanted side-effects.
RNAi based high-throughput functional profiling was performed
using two prostate cancer cell lines. Since siRNAs are known to
induce off-target effects [61], four siRNAs per gene were initially
used. In addition, to validate the results, positive and negative
controls were utilized, and the cell proliferation siRNA screen was
conducted in triplicates in both of the cell lines. Furthermore,
potential induction of apoptosis by the siRNAs was also evaluated
to gain further confirmation, and the results from the functional
assays were validated in vitro using two siRNAs per each target
gene. As evidenced by the high rate of hit siRNAs especially in
LNCaP cells, the focused approach was successful in maximizing
the amount of potential prostate cancer relevant drug targets
identified. In conclusion, the combinatorial usage of microarray
and RNAi techniques yielded in a large number of putative novel
drug targets, with biomarker potential, for future development of
targeted and personalized prostate cancer management.
Based on RNAi screening results, genome-wide gene expression
patterns and novelty AIM1, ERGIC1 and TMED3 and TPX2 were
selected for further validation. Validation experiments included
target mRNA expression analysis in cultured prostate cell lines, as
well as in clinical prostate samples. All of the four candidate targets
were found to be highly expressed especially in the prostate cancer
cell lines studied and showed highest expression either in VCaP or
LNCaP cells, utilized in the HT RNAi screens. The clinical
validation showed that the putative drug targets were widely
expressed in clinical prostate cancer samples. Moreover, AIM1,
ERGIC1, and TPX2 were shown to be highly expressed specifically
in prostate cancer tissues, thereby confirming the results of the
bioinformatic surveys. Interestingly, even though AIM1, ERGIC1,
TMED3 and TPX2 were partially expressed in separate subsets of
prostate cancers, all of the candidate target genes were found to be
regulated by ERG oncogene as well as androgens highlighting the
significance of ERG and androgens in promoting prostate
oncogenesis.
As reports of the role of AIM1 in different cancers are
controversial [43,46–48], further studies are needed to evaluate
its potential in cancer management. However, our results indicate
that AIM1 is highly expressed in primary prostate cancers as well
as in cultured androgen-independent prostate cancer cells, and
support the potential of AIM1 inhibition in prostate cancer
management, most likely in combinatorial treatment approaches.
Furthermore, the co-expression gene signature analysis supports
the earlier report associating AIM1 with the regulation of cell
morphology and shape [42].
ERGIC1 and TMED3 expression associated with ER and Golgi
apparatus function. Although inhibition of ER and Golgi function
has been suggested a promising opportunity for targeted cancer
therapy, ERGIC1 and TMED3 have not been previously described
as candidate cancer targets [51,52]. Moreover, this study
associates ERGIC1 and TMED3 expression with ERG oncogene
expression, supporting their potential in the management of
prostate cancer. Since ERGIC1 was highly expressed in most
primary prostate tumors, and ERGIC1 silencing was able to
Figure 3. Validation of AIM1, ERGIC1, TMED3 and TPX2 expression and silencing in prostate cell lines. A. The mRNA expression of target
genes in 6 prostate cancer (VCaP, PC-3, MDA-PCa-2b, LNCaP, DU145 and 22Rv1) and 3 non-malignant (RWPE-1, PrEc, EP156T) prostate cell lines. For
each gene the relative mRNA expression in RWPE-1 cell line was set to 1. B. Validation of target gene silencing. The mRNA level of each gene in
control sample has been set as 100%. C. The effect of target gene silencing on VCaP and LNCaP cell viability at 72 h timepoint. D. The effect of target
gene silencing on induction of apoptosis in VCaP and LNCaP cells at 72 h timepoint. The results have been compared to scrambled siRNA induced
changes and the significance of the anti-proliferative and pro-apoptotic effects have been indicated. KIF11 siRNA has been used as the positive
control.
doi:10.1371/journal.pone.0039801.g003
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target especially for the ERG oncogene expressing tumors.
Previous study has shown that ETS (ETS1) transcription factor
mediates adaptation to ER stress in melanoma cells [62],
supporting the potential role of ERG in the regulation of ER
function related genes in prostate cancer. Furthermore, the gene
co-expression signatures indicate that ERGIC1 and TMED3 are
expressed together with genes involved in cellular redox home-
ostasis, in agreement to our earlier results demonstrating that ERG
oncogene expressing cancer cells are sensitive to oxidative stress
inducers [30,63]. Finally, both of the ER related genes were
upregulated by androgens, supporting the earlier results suggest-
ing, that the expression of ER stress response genes is regulated by
androgen in prostate cancer cells [64].
TPX2 has been proposed as a potential drug target in multiple
cancer types [56–58], and our results reveal TPX2 as a potent
candidate drug target also in prostate cancer. We showed that
TPX2 is regulated by AR and androgens, and that TPX2 silencing
downregulates AR signaling. Furthermore, in accordance to the
previous studies associating TPX2 expression with poor survival in
lung cancer and astrocytoma, as well as with aggressive disease in
meningiomas [53–55], our results indicated that TPX2 expression
Figure 4. Validation of AIM1, ERGIC1, TMED3 and TPX2 expression in clinical prostate tissue samples. A. The mRNA expression of target
genes in 33 primary prostate cancer and 3 non-malignant prostate tissue samples. The mean expression the non-malignant samples has been set as
1. B. Heatmap visualization of the gene-wise scaled relative mRNA expression values for AIM1, ERGIC1, TMED3, TPX2, ERG, and AR in 33 primary
prostate cancer tissues. The heatmap is drawn based on unsupervised hierarchical clustering of the expression values. Relative mean expression level
in normal control samples was set as 0. C. Co-expression patterns between ERGIC1 and AR mRNA, as well as TMED3 and AR mRNA in 33 primary
prostate cancer samples. D. Association of ERGIC1 and TMED3 mRNA expression with ERG mRNA expression in the ERG positive primary prostate
tumors (n=19). E. Relative mRNA expression of AIM1 in primary prostate cancer samples in comparison to patient age. F. Relative mRNA expression
of TPX2 in primary prostate cancer samples in comparison to occurrence of PSA failure, WHO tumor grade and patient age.
doi:10.1371/journal.pone.0039801.g004
Figure 5. AIM1, ERGIC1, TMED3 and TPX2 expression interrelates with ERG and AR oncogene expression in vitro.A .The effect of 48 h ERG
silencing on the expression of the target genes in VCaP cells. B. The effect of 48 h AR silencing on the expression of the target genes in VCaP and
LNCaP cells. C. The effect of 24 h androgen deprivation and sequential 24 h androgen stimulation (10 nM R1881) on the expression the target genes
in LNCaP cells. D. The level of target mRNA expression in LNCaP cells cultured in normal media (FBS) and in chargoal-stripped (CS-FBS) androgen
ablated media. E. The effect of 72 h TPX2 silencing on the protein expression of AR and PSA. b-actin has been used as a loading control. The statistical
significance of the results in comparison to control experiment have been indicated.
doi:10.1371/journal.pone.0039801.g005
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age in prostate cancer. Taken together, TPX2 is a candidate
therapeutic target in majority of prostate cancers, possibly also in
advanced and castration-resistant disease.
In conclusion, this study illustrates the power of gene expression
data analysis coupled with high-throughput RNAi in the
exploration of potential novel target genes for cancer manage-
ment. We present ERGIC1 and TMED3 as candidate drug targets
for ERG oncogene positive tumors, whereas TPX2 expression was
associated with mitotic and aggressive disease. AIM1 was highly
expressed in most of the prostate cancers studied, suggesting a
broad therapeutic target group. Further studies are required to
validate the in vivo therapeutic relevance of these promising targets.
Furthermore, in addition to the four in vitro validated potential
drug targets, the results from this study provide several other
starting points for future preclinical and eventually clinical efforts
to treat prostate cancer.
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Figure S1 The mRNA expression of AIM1, ERGIC1,
TMED3 and TPX2 in clinical tissue samples based on the
data available in GeneSapiens database.
(PDF)
Figure S2 Validation of target gene silencing of ER-
GIC1, TMED3 and TPX2 at protein level. b-actin has been
used as a loading control.
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Figure S3 A. The effect of AIM1, ERGIC1 and TMED3
silencing on the protein expression of AR and PSA in VCaP
and LNCaP cells. b-actin has been used as a loading control. B.
The effect of TPX2 silencing on the mRNA expression of AR and
PSA in LNCaP cells.
(PDF)
Figure S4 The effect of 72 h target gene silencing on cell
viability and induction of apoptosis in LNCaP deriva-
tives cultured in normal serum containing media (FBS)
and in androgen ablated media (CS-FBS). The results have
been compared to scrambled siRNA induced changes and the
significance of the anti-proliferative and pro-apoptotic effects have
been indicated. KIF11 siRNA has been used as the positive
control.
(PDF)
Figure S5 The effect of ERGIC1 silencing on the mRNA
expression of ERG.
(PDF)
Table S1 Primers and probes utilized in qRT-PCR
analysis.
(PDF)
Table 1. Functional gene ontology annotations for the genes
co-expressed (R .0.5 and P,0.001) with AIM1, ERGIC1, TMED3
or TPX2 in clinical prostate cancer samples (n=66–329).
Gene Annotation P-value
AIM1 Cellular compartment
Large ribosomal unit 9.0E-03
Mitochondrion 4.2E-02
Disease
Cardiovascular Disease 4,50E-04 - 3,48E-02
Molecular and cellular functions
Cell Morphology 8,46E-04 - 4,72E-02
Lipid Metabolism 2,89E-03 - 4,72E-02
Molecular Transport 2,89E-03 - 4,72E-02
Biological Processes
Transition metal ion transport 8.6E-04
Protein oligomerization 9.8E-03
Sterol metabolic process 2.1E-02
ERGIC1 Cellular compartment
ER-Golgi intermediate compartment 1.5E-05
Mitochondrion 2.6E-05
Disease
Cancer 1,55E-05 - 3,44E-02
Molecular and cellular functions
Amino Acid Metabolism 5,46E-08 - 3,44E-02
Small Molecule Biochemistry 5,46E-08 - 3,44E-02
Energy Production 8,69E-06 - 3,44E-02
Biological Processes
Carboxylic acid catabolic process 1.3E-09
Oxidation reduction 1.3E-05
Golgi vesicle transport 2.5E-05
TMED3 Cellular compartment
Endoplasmic reticulum 1.7E-08
ER-Golgi intermediate compartment 1.5E-03
Disease
Dermatological Diseases and Conditions 4,83E-03 - 4,71E-02
Molecular and cellular functions
Lipid Metabolism 1,39E-03 - 4,72E-02
Small Molecule Biochemistry 1,39E-03 - 4,72E-02
Cell Morphology 2,32E-03 - 4,72E-02
Biological Processes
Intracellular protein transport 2.3E-04
Cell redox homeostasis 1.7E-04
Regulation of caspase activity 5.2E-03
TPX2 Cellular compartment
Chromosome, centromeric region 1.1E-16
Microtubule cytoskeleton 7.3E-15
Disease
Cancer 2,88E-09 - 4,96E-02
Molecular and cellular functions
Cell Cycle 1,01E-22 - 4,70E-02
Cellular Assembly and Organization 1,11E-13 - 4,68E-02
DNA Replication, Recombination, and Repair1,11E-13 - 4,68E-02
Table 1. Cont.
Gene Annotation P-value
Biological Processes
M phase of mitotic cell cycle 9.4E-29
Microtubule-based process 4.2E-11
DNA metabolic process 8.8E-11
doi:10.1371/journal.pone.0039801.t001
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apoptosis assays in VCaP and LNCaP cell lines. The
results are presented as B-score, and the results exceeding the hit
limit (-2 SD in cell viability and 3 SD in apoptosis) have been
indicated with colour.
(XLS)
Table S3 The genes co-expressed (R .0.5 and P,0.001)
with AIM1, ERGIC1, TMED3 or TPX2 in clinical prostate
cancer samples (n=66–329) in silico, and utilized in
Table 1.
(XLS)
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